keyword
MENU ▼
Read by QxMD icon Read
search

David P. Steensma

keyword
https://www.readbyqxmd.com/read/27913464/new-challenges-in-evaluating-anemia-in-older-persons-in-the-era-of-molecular-testing
#1
David P Steensma
Anemia is common in older persons, and often remains unexplained despite a thorough clinical history, physical examination, and focused laboratory testing, including marrow aspiration, biopsy, and karyotyping. The advent of molecular genetic testing panels in hematology clinical practice has complicated the evaluation of older patients with unexplained anemia. While the presence of a somatic mutation provides evidence of clonal hematopoiesis and may support a diagnosis of a hematologic neoplasm such as one of the myelodysplastic syndromes (MDS), with rare exceptions, individual mutations are not strongly associated with one specific diagnosis, nor are they by themselves diagnostic of neoplasia...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27878822/wide-variations-in-blood-product-transfusion-practices-among-providers-who-care-for-patients-with-acute-leukemia-in-the-united-states
#2
Alexander B Pine, Eun-Ju Lee, Mikkael Sekeres, David P Steensma, Daniel Zelterman, Thomas Prebet, Amy DeZern, Rami Komrokji, Mark Litzow, Selina Luger, Richard Stone, Harry P Erba, Guillermo Garcia-Manero, Alfred I Lee, Nikolai A Podoltsev, Lisa Barbarotta, Stephanie Kasberg, Jeanne E Hendrickson, Steven D Gore, Amer M Zeidan
BACKGROUND: Transfusion of blood products is a key component of the supportive management in patients with acute leukemia (AL). However high-quality trial evidence and clinical outcome data to support specific transfusion goals for blood products for patients with AL remain limited leading to diverse transfusion practices. The primary objective of this study was to determine the spectrum of transfusion patterns in a variety of care settings among providers who treat AL patients. STUDY DESIGN AND METHODS: A 31-question survey queried providers caring for AL patients about the existence of institutional guidelines for transfusion of blood products, transfusion triggers for hemoglobin (Hb), platelets (PLTs), and fibrinogen in various settings including inpatient and outpatient and before procedures...
November 22, 2016: Transfusion
https://www.readbyqxmd.com/read/27776290/good-riddance-to-the-term-refractory-anemia-in-myelodysplastic-syndromes
#3
David P Steensma
The term "refractory anemia" was used in 1937 by Cornelius Parker Rhoads to describe patients whose anemia did not improve after treatment with liver extract or iron salts, and this term has been used to denote patients with certain subtypes of myelodysplastic syndromes (MDS) since the 1976 and 1982 French-American-British (FAB) classifications of acute leukemias and MDS. In 2016, the World Health Organization (WHO) proposed elimination of "refractory anemia" in a more general proposal for reclassification of myeloid neoplasia...
October 17, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27774847/differential-response-to-hypomethylating-agents-based-on-sex-a-report-on-behalf-of-the-mds-clinical-research-consortium-mds-crc
#4
Amy E DeZern, Amer M Zeidan, John Barnard, Wesley Hand, Najla Al Ali, Francis Brown, Cassie Zimmerman, Gail J Roboz, Guillermo Garcia-Manero, David P Steensma, Rami S Komrokji, Mikkael A Sekeres
First-line therapy for higher-risk myelodysplastic syndromes (MDS) includes decitabine (DAC) or azacitidine (AZA). Variables have not identified differential response rates between these. We assessed the influence of patient sex on outcomes including overall survival (OS) in 642 patients with higher-risk MDS treated with AZA or DAC. DAC-treated patients (35% of females, 31% of males) had marginally better OS than AZA-treated patients (p = .043), (median OS of 18.7 months versus 16.4 months), but the difference varied strongly by sex...
October 24, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27621329/hematopoietic-cell-transplantation-for-myelodysplastic-syndromes
#5
REVIEW
Vijaya Raj Bhatt, David P Steensma
Allogeneic hematopoietic cell transplantation (HCT) offers the only potential cure for patients with myelodysplastic syndromes (MDS). However, with current approaches to HCT, many older patients with comorbidities are poor HCT candidates, and treatment-related morbidity and mortality may offset benefit for patients with lower-risk disease. Consequently, selection of patients with MDS for HCT should take into consideration disease risk category including mutational status, HCT comorbidity index, functional status, donor options, and available institutional resources...
September 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27609540/putting-it-all-together-in-cmml-risk-stratification
#6
David P Steensma
No abstract text is available yet for this article.
September 8, 2016: Blood
https://www.readbyqxmd.com/read/27594194/j-robin-warren-helicobacter-pylori-and-peptic-ulcer
#7
David P Steensma, Robert A Kyle, Marc A Shampo
No abstract text is available yet for this article.
September 2016: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/27538433/connect-mds-aml-design-of-the-myelodysplastic-syndromes-and-acute-myeloid-leukemia-disease-registry-a-prospective-observational-cohort-study
#8
David P Steensma, Medrdad Abedi, Rafael Bejar, Christopher R Cogle, Kathryn Foucar, Guillermo Garcia-Manero, Tracy I George, David Grinblatt, Rami Komrokji, Xiaomei Ma, Jaroslaw Maciejewski, Daniel A Pollyea, Michael R Savona, Bart Scott, Mikkael A Sekeres, Michael A Thompson, Arlene S Swern, Melissa Nifenecker, Mary M Sugrue, Harry Erba
BACKGROUND: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are myeloid neoplasms in which outgrowth of neoplastic clones disrupts normal hematopoiesis. Some patients with unexplained persistent cytopenias may not meet minimal diagnostic criteria for MDS but an alternate diagnosis is not apparent; the term idiopathic cytopenia of undetermined significance (ICUS) has been used to describe this state. MDS and AML occur primarily in older patients who are often treated outside the clinical trial setting...
August 19, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27492253/targeting-splicing-in-the-treatment-of-myelodysplastic-syndromes-and-other-myeloid-neoplasms
#9
Charlotte K Brierley, David P Steensma
Genome sequencing of primary cells from patients with myelodysplastic syndromes (MDS) led to the identification of recurrent heterozygous mutations in gene encoding components of the spliceosome, the cellular machinery which processes pre-messenger RNA (mRNA) to mature mRNA during gene transcription. Splicing mutations are mutually exclusive with one another and collectively represent the most common mutation class in MDS, occurring in approximately 60 % of patients overall and more than 80 % of those with ring sideroblasts...
August 5, 2016: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/27479034/the-public-repository-of-xenografts-enables-discovery-and-randomized-phase-ii-like-trials-in-mice
#10
Elizabeth C Townsend, Mark A Murakami, Alexandra Christodoulou, Amanda L Christie, Johannes Köster, Tiffany A DeSouza, Elizabeth A Morgan, Scott P Kallgren, Huiyun Liu, Shuo-Chieh Wu, Olivia Plana, Joan Montero, Kristen E Stevenson, Prakash Rao, Raga Vadhi, Michael Andreeff, Philippe Armand, Karen K Ballen, Patrizia Barzaghi-Rinaudo, Sarah Cahill, Rachael A Clark, Vesselina G Cooke, Matthew S Davids, Daniel J DeAngelo, David M Dorfman, Hilary Eaton, Benjamin L Ebert, Julia Etchin, Brant Firestone, David C Fisher, Arnold S Freedman, Ilene A Galinsky, Hui Gao, Jacqueline S Garcia, Francine Garnache-Ottou, Timothy A Graubert, Alejandro Gutierrez, Ensar Halilovic, Marian H Harris, Zachary T Herbert, Steven M Horwitz, Giorgio Inghirami, Andrew M Intlekofer, Moriko Ito, Shai Izraeli, Eric D Jacobsen, Caron A Jacobson, Sébastien Jeay, Irmela Jeremias, Michelle A Kelliher, Raphael Koch, Marina Konopleva, Nadja Kopp, Steven M Kornblau, Andrew L Kung, Thomas S Kupper, Nicole R LeBoeuf, Ann S LaCasce, Emma Lees, Loretta S Li, A Thomas Look, Masato Murakami, Markus Muschen, Donna Neuberg, Samuel Y Ng, Oreofe O Odejide, Stuart H Orkin, Rachel R Paquette, Andrew E Place, Justine E Roderick, Jeremy A Ryan, Stephen E Sallan, Brent Shoji, Lewis B Silverman, Robert J Soiffer, David P Steensma, Kimberly Stegmaier, Richard M Stone, Jerome Tamburini, Aaron R Thorner, Paul van Hummelen, Martha Wadleigh, Marion Wiesmann, Andrew P Weng, Jens U Wuerthner, David A Williams, Bruce M Wollison, Andrew A Lane, Anthony Letai, Monica M Bertagnolli, Jerome Ritz, Myles Brown, Henry Long, Jon C Aster, Margaret A Shipp, James D Griffin, David M Weinstock
No abstract text is available yet for this article.
July 11, 2016: Cancer Cell
https://www.readbyqxmd.com/read/27443511/acute-erythroid-leukemia-with-20-bone-marrow-blasts-is-clinically-and-biologically-similar-to-myelodysplastic-syndrome-with-excess-blasts
#11
Sa A Wang, Keyur P Patel, Olga Pozdnyakova, Jie Peng, Zhuang Zuo, Paola Dal Cin, David P Steensma, Robert P Hasserjian
In acute erythroleukemia, erythroid/myeloid subtype, blasts usually comprise 5-19% of total bone marrow cells, similar to the myelodysplastic syndrome subtype refractory anemia with excess blasts; recent studies have raised the question if acute erythroleukemia should be considered as a myelodysplastic syndrome subtype. We reviewed 77 de novo acute erythroleukemia and 279 de novo refractory anemia with excess blasts from three large medical centers. Compared to refractory anemia with excess blasts, acute erythroleukemia patients had higher total bone marrow blasts, lower platelets, hemoglobin, and absolute neutrophil counts, with more patients being assigned a very-poor-karyotype risk and very-high Revised International Prognostic Scoring System score...
October 2016: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/27378050/elizabeth-blackburn-and-maintenance-of-telomeres
#12
David P Steensma, Robert A Kyle, Marc A Shampo
No abstract text is available yet for this article.
July 2016: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/27264037/potentially-avoidable-hospital-admissions-in-older-patients-with-acute-myeloid-leukaemia-in-the-usa-a-retrospective-analysis
#13
Areej El-Jawahri, Tanya Keenan, Gregory A Abel, David P Steensma, Thomas W LeBlanc, Yi-Bin Chen, Gabriela Hobbs, Lara Traeger, Amir T Fathi, Daniel J DeAngelo, Martha Wadleigh, Karen K Ballen, Philip C Amrein, Richard M Stone, Jennifer S Temel
BACKGROUND: Older adults (≥60 years of age) with acute myeloid leukaemia spend a substantial proportion of their life in hospital after diagnosis. We examined reasons for their hospital admissions and identified potentially avoidable hospital admissions (PAH) in this age group in the USA. METHODS: In this retrospective analysis, we examined the reasons for hospital admissions in older patients diagnosed with and treated for acute myeloid leukaemia at two tertiary care hospitals in the USA...
June 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27171984/phase-2-study-of-intensified-chemotherapy-and-allogeneic-hematopoietic-stem-cell-transplantation-for-older-patients-with-acute-lymphoblastic-leukemia
#14
Amir T Fathi, Daniel J DeAngelo, Kristen E Stevenson, Jonathan E Kolitz, Julie D Asch, Philip C Amrein, Eyal C Attar, David P Steensma, Martha Wadleigh, Julia Foster, Christine Connolly, Ilene Galinsky, Craig E Devoe, Richard M Stone, Donna S Neuberg, Karen K Ballen
BACKGROUND: Outcomes among older patients with acute lymphoblastic leukemia remain poor. This study sought to determine the efficacy of an intensified, multi-agent approach derived from a Dana-Farber consortium trial in younger adults for patients older than 50 years (trial identifier NCT00973752). METHODS: The primary endpoint was overall survival (OS) at 1 year. Patients received induction chemotherapy with vincristine, prednisone, doxorubicin, and pegylated asparaginase...
August 1, 2016: Cancer
https://www.readbyqxmd.com/read/27153389/allogeneic-transplantation-is-not-superior-to-chemotherapy-in-most-patients-over-40%C3%A2-years-of-age-with-philadelphia-negative-acute-lymphoblastic-leukemia-in-first-remission
#15
Ofir Wolach, Kristen E Stevenson, Martha Wadleigh, Daniel J DeAngelo, David P Steensma, Karen K Ballen, Robert J Soiffer, Joseph H Antin, Donna S Neuberg, Vincent T Ho, Richard M Stone
Survival of patients ≥40 years of age with Philadelphia-negative acute lymphoblastic leukemia (ALL) remains poor with current therapeutic approaches. It is unknown whether allogeneic hematopoietic stem-cell transplantation (HSCT) in first remission confers a survival benefit compared to a chemotherapy-only approach. We retrospectively compared the outcome of patients >40 years treated with HSCT or chemotherapy alone in first remission (n = 40 in each cohort). Three-year overall survival (OS) and disease-free survival (DFS) were not significantly different between the chemotherapy-only and HSCT groups (OS, 46% [31-68] vs...
August 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/27150219/barry-james-marshall-discovery-of-helicobacter-pylori-as-a-cause-of-peptic-ulcer
#16
Robert A Kyle, David P Steensma, Marc A Shampo
No abstract text is available yet for this article.
May 2016: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/27070704/the-public-repository-of-xenografts-enables-discovery-and-randomized-phase-ii-like-trials-in-mice
#17
Elizabeth C Townsend, Mark A Murakami, Alexandra Christodoulou, Amanda L Christie, Johannes Köster, Tiffany A DeSouza, Elizabeth A Morgan, Scott P Kallgren, Huiyun Liu, Shuo-Chieh Wu, Olivia Plana, Joan Montero, Kristen E Stevenson, Prakash Rao, Raga Vadhi, Michael Andreeff, Philippe Armand, Karen K Ballen, Patrizia Barzaghi-Rinaudo, Sarah Cahill, Rachael A Clark, Vesselina G Cooke, Matthew S Davids, Daniel J DeAngelo, David M Dorfman, Hilary Eaton, Benjamin L Ebert, Julia Etchin, Brant Firestone, David C Fisher, Arnold S Freedman, Ilene A Galinsky, Hui Gao, Jacqueline S Garcia, Francine Garnache-Ottou, Timothy A Graubert, Alejandro Gutierrez, Ensar Halilovic, Marian H Harris, Zachary T Herbert, Steven M Horwitz, Giorgio Inghirami, Andrew M Intlekoffer, Moriko Ito, Shai Izraeli, Eric D Jacobsen, Caron A Jacobson, Sébastien Jeay, Irmela Jeremias, Michelle A Kelliher, Raphael Koch, Marina Konopleva, Nadja Kopp, Steven M Kornblau, Andrew L Kung, Thomas S Kupper, Nicole LaBoeuf, Ann S LaCasce, Emma Lees, Loretta S Li, A Thomas Look, Masato Murakami, Markus Muschen, Donna Neuberg, Samuel Y Ng, Oreofe O Odejide, Stuart H Orkin, Rachel R Paquette, Andrew E Place, Justine E Roderick, Jeremy A Ryan, Stephen E Sallan, Brent Shoji, Lewis B Silverman, Robert J Soiffer, David P Steensma, Kimberly Stegmaier, Richard M Stone, Jerome Tamburini, Aaron R Thorner, Paul van Hummelen, Martha Wadleigh, Marion Wiesmann, Andrew P Weng, Jens U Wuerthner, David A Williams, Bruce M Wollison, Andrew A Lane, Anthony Letai, Monica M Bertagnolli, Jerome Ritz, Myles Brown, Henry Long, Jon C Aster, Margaret A Shipp, James D Griffin, David M Weinstock
More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them...
April 11, 2016: Cancer Cell
https://www.readbyqxmd.com/read/27018651/contract-research-organizations-in-oncology-clinical-research-challenges-and-opportunities
#18
Daniel A Roberts, Hagop M Kantarjian, David P Steensma
Contract research organizations (CROs) represent a multibillion dollar industry that is firmly embedded in the contemporary clinical trial process. Over the past 30 years, and especially within the last decade, the reach of CROs has extended to service all phases of drug trials in an increasingly global research environment. The presence of CROs is particularly noticeable in medical oncology because of the large number of investigational compounds developed to treat cancer that are currently undergoing testing in human subjects...
May 15, 2016: Cancer
https://www.readbyqxmd.com/read/26992944/the-efficacy-of-current-prognostic-models-in-predicting-outcome-of-patients-with-myelodysplastic-syndromes-at-the-time-of-hypomethylating-agent-failure
#19
LETTER
Aziz Nazha, Rami S Komrokji, Guillermo Garcia-Manero, John Barnard, Gail J Roboz, David P Steensma, Amy E DeZern, Katrina Zell, Cassie Zimmerman, Najla Al Ali, Elias Jabbour, Molly D Greenberg, Hagop M Kantarjian, Jaroslaw P Maciejewski, Alan F List, Mikkael A Sekeres
No abstract text is available yet for this article.
June 2016: Haematologica
https://www.readbyqxmd.com/read/26968357/rigosertib-versus-best-supportive-care-for-patients-with-high-risk-myelodysplastic-syndromes-after-failure-of-hypomethylating-drugs-ontime-a-randomised-controlled-phase-3-trial
#20
Guillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, Maria R Baer, Mikkael A Sekeres, Gail J Roboz, Gianluca Gaidano, Bart L Scott, Peter Greenberg, Uwe Platzbecker, David P Steensma, Suman Kambhampati, Karl-Anton Kreuzer, Lucy A Godley, Ehab Atallah, Robert Collins, Hagop Kantarjian, Elias Jabbour, Francois E Wilhelm, Nozar Azarnia, Lewis R Silverman
BACKGROUND: Hypomethylating drugs are the standard treatment for patients with high-risk myelodysplastic syndromes. Survival is poor after failure of these drugs; there is no approved second-line therapy. We compared the overall survival of patients receiving rigosertib and best supportive care with that of patients receiving best supportive care only in patients with myelodysplastic syndromes with excess blasts after failure of azacitidine or decitabine treatment. METHODS: We did this randomised controlled trial at 74 hospitals and university medical centres in the USA and Europe...
April 2016: Lancet Oncology
keyword
keyword
64671
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"